Last 12 months
Inside the activity.
0 purchase rows · 116 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 6 |
| Jan 2026 | 0 | 5 |
| Feb 2026 | 0 | 17 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 23 |
| May 2026 | 0 | 15 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 5 |
| Sep 2026 | 0 | 41 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2026 Filed Jun 16, 2026 20:42 UTC |
Baynes Roy D.Director
|
Exercise / conversionStock option (right to buy) · Derivative | 4,500 | $0.00 Strike: $21.38 | $0.00 |
DisclosureSEC source: 0001680739-26-000014 · form4-06162026_080649.xml · derivative · entry 3 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,500 shares Expires 2032-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 20:42 UTC |
Baynes Roy D.Director
|
SaleCommon Stock | 4,500 | $50.00 | $225,000.00 |
DisclosureSEC source: 0001680739-26-000014 · form4-06162026_080649.xml · nonDerivative · entry 2 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,500 F1 · kind: This sale was made pursuant to a written plan adopted on November 17, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 20:42 UTC |
Baynes Roy D.Director
|
Exercise / conversionCommon Stock | 4,500 | $21.38 | $96,210.00 |
DisclosureSEC source: 0001680739-26-000014 · form4-06162026_080649.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 19, 2026 Filed May 21, 2026 21:00 UTC |
LYONS GARY ADirector
|
GrantStock option (right to buy) · Derivative | 12,000 | $0.00 Strike: $42.26 | $0.00 |
DisclosureSEC source: 0001123343-26-000004 · form4-05212026_050508.xml · derivative · entry 2 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2036-05-19 F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · derivative.exercise_date: The equity award vests over a one year period. Read SEC document |
| May 19, 2026 Filed May 21, 2026 21:00 UTC |
LYONS GARY ADirector
|
GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001123343-26-000004 · form4-05212026_050508.xml · nonDerivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,500 F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · shares: The equity award vests over a one year period. Read SEC document |
| May 19, 2026 Filed May 21, 2026 21:00 UTC |
Orwin John ADirector
|
GrantStock option (right to buy) · Derivative | 12,000 | $0.00 Strike: $42.26 | $0.00 |
DisclosureSEC source: 0001477384-26-000008 · form4-05212026_050512.xml · derivative · entry 2 Orwin John A · CIK 0001477384 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2036-05-19 F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · derivative.exercise_date: The equity award vests over a one year period. Read SEC document |
| May 19, 2026 Filed May 21, 2026 21:00 UTC |
Orwin John ADirector
|
GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001477384-26-000008 · form4-05212026_050512.xml · nonDerivative · entry 1 Orwin John A · CIK 0001477384 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,375 F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · shares: The equity award vests over a one year period. Read SEC document |
| May 19, 2026 Filed May 21, 2026 21:00 UTC |
Squarer RonDirector
|
GrantStock option (right to buy) · Derivative | 12,000 | $0.00 Strike: $42.26 | $0.00 |
DisclosureSEC source: 0001454001-26-000002 · form4-05212026_050515.xml · derivative · entry 2 Squarer Ron · CIK 0001454001 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2036-05-19 F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · derivative.exercise_date: The equity award vests over a one year period. Read SEC document |
| May 19, 2026 Filed May 21, 2026 21:00 UTC |
Squarer RonDirector
|
GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001454001-26-000002 · form4-05212026_050515.xml · nonDerivative · entry 1 Squarer Ron · CIK 0001454001 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,375 F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · shares: The equity award vests over a one year period. Read SEC document |
| May 19, 2026 Filed May 21, 2026 21:00 UTC |
Williams Brinkley RuthDirector
|
GrantStock option (right to buy) · Derivative | 12,000 | $0.00 Strike: $42.26 | $0.00 |
DisclosureSEC source: 0001344381-26-000004 · form4-05212026_050518.xml · derivative · entry 2 Williams Brinkley Ruth · CIK 0001344381 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2036-05-19 F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · derivative.exercise_date: The equity award vests over a one year period. Read SEC document |
| May 19, 2026 Filed May 21, 2026 21:00 UTC |
Williams Brinkley RuthDirector
|
GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001344381-26-000004 · form4-05212026_050518.xml · nonDerivative · entry 1 Williams Brinkley Ruth · CIK 0001344381 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,750 F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · shares: The equity award vests over a one year period. Read SEC document |
| May 19, 2026 Filed May 21, 2026 21:00 UTC |
Poole SandraDirector
|
GrantStock option (right to buy) · Derivative | 12,000 | $0.00 Strike: $42.26 | $0.00 |
DisclosureSEC source: 0001619622-26-000002 · form4-05212026_050514.xml · derivative · entry 2 Poole Sandra · CIK 0001619622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2036-05-19 F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · derivative.exercise_date: The equity award vests over a one year period. Read SEC document |
| May 19, 2026 Filed May 21, 2026 21:00 UTC |
Poole SandraDirector
|
GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001619622-26-000002 · form4-05212026_050514.xml · nonDerivative · entry 1 Poole Sandra · CIK 0001619622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,000 F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · shares: The equity award vests over a one year period. Read SEC document |
| May 19, 2026 Filed May 21, 2026 21:00 UTC |
Meckler Jeffrey ADirector
|
GrantStock option (right to buy) · Derivative | 12,000 | $0.00 Strike: $42.26 | $0.00 |
DisclosureSEC source: 0001506916-26-000003 · form4-05212026_050510.xml · derivative · entry 2 Meckler Jeffrey A · CIK 0001506916 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2036-05-19 F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · derivative.exercise_date: The equity award vests over a one year period. Read SEC document |
| May 19, 2026 Filed May 21, 2026 21:00 UTC |
Meckler Jeffrey ADirector
|
GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001506916-26-000003 · form4-05212026_050510.xml · nonDerivative · entry 1 Meckler Jeffrey A · CIK 0001506916 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,500 F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · shares: The equity award vests over a one year period. Read SEC document |
| May 19, 2026 Filed May 21, 2026 21:00 UTC |
Coughlin TimothyDirector
|
GrantStock option (right to buy) · Derivative | 12,000 | $0.00 Strike: $42.26 | $0.00 |
DisclosureSEC source: 0001376043-26-000006 · form4-05212026_050506.xml · derivative · entry 2 Coughlin Timothy · CIK 0001376043 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2036-05-19 F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · derivative.exercise_date: The equity award vests over a one year period. Read SEC document |
| May 19, 2026 Filed May 21, 2026 21:00 UTC |
Coughlin TimothyDirector
|
GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001376043-26-000006 · form4-05212026_050506.xml · nonDerivative · entry 1 Coughlin Timothy · CIK 0001376043 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,250 F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · shares: The equity award vests over a one year period. Read SEC document |
| May 19, 2026 Filed May 21, 2026 21:00 UTC |
Bruhn Suzanne LouiseDirector
|
GrantStock option (right to buy) · Derivative | 12,000 | $0.00 Strike: $42.26 | $0.00 |
DisclosureSEC source: 0001517790-26-000002 · form4-05212026_050504.xml · derivative · entry 2 Bruhn Suzanne Louise · CIK 0001517790 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2036-05-19 F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · derivative.exercise_date: The equity award vests over a one year period. Read SEC document |
| May 19, 2026 Filed May 21, 2026 21:00 UTC |
Bruhn Suzanne LouiseDirector
|
GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001517790-26-000002 · form4-05212026_050504.xml · nonDerivative · entry 1 Bruhn Suzanne Louise · CIK 0001517790 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,750 F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · shares: The equity award vests over a one year period. Read SEC document |
| May 19, 2026 Filed May 21, 2026 21:00 UTC |
Baynes Roy D.Director
|
GrantStock option (right to buy) · Derivative | 12,000 | $0.00 Strike: $42.26 | $0.00 |
DisclosureSEC source: 0001680739-26-000012 · form4-05212026_050501.xml · derivative · entry 2 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2036-05-19 F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · derivative.exercise_date: The equity award vests over a one year period. Read SEC document |
| May 19, 2026 Filed May 21, 2026 21:00 UTC |
Baynes Roy D.Director
|
GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001680739-26-000012 · form4-05212026_050501.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,500 F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · shares: The equity award vests over a one year period. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:05 UTC |
Coughlin TimothyDirector
|
SaleCommon Stock | 3,250 | $43.49 | $141,342.50 |
DisclosureSEC source: 0001376043-26-000005 · form4-05192026_040501.xml · nonDerivative · entry 1 Coughlin Timothy · CIK 0001376043 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,250 F1 · kind: This sale was made pursuant to a written plan adopted on November 19, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 06, 2026 Filed May 7, 2026 00:00 UTC |
Inrig JulaCHIEF MEDICAL OFFICER
|
SaleCommon Stock | 311 | $43.95 | $13,668.45 |
DisclosureSEC source: 0001902368-26-000006 · form4-05062026_080509.xml · nonDerivative · entry 5 Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 113,238 F4 · kind: This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. Read SEC document |
| May 06, 2026 Filed May 7, 2026 00:00 UTC |
ROTE WILLIAM E.Chief Research Officer
|
SaleCommon Stock | 2,763 | $43.95 | $121,433.85 |
DisclosureSEC source: 0001698262-26-000004 · form4-05062026_080513.xml · nonDerivative · entry 2 ROTE WILLIAM E. · CIK 0001698262 · Chief Research Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 115,474 F2 · kind: This sale was made pursuant to a written plan adopted on May 29, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. Read SEC document |
| May 06, 2026 Filed May 7, 2026 00:00 UTC |
REED ELIZABETH EChief Legal Officer and GC
|
SaleCommon Stock | 2,076 | $43.95 | $91,240.20 |
DisclosureSEC source: 0001283303-26-000009 · form4-05062026_080511.xml · nonDerivative · entry 5 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,211 F4 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. Read SEC document |
| May 06, 2026 Filed May 7, 2026 00:00 UTC |
Cline Christopher R.CHIEF FINANCIAL OFFICER
|
SaleCommon Stock | 310 | $43.95 | $13,624.50 |
DisclosureSEC source: 0001943192-26-000004 · form4-05062026_080501.xml · nonDerivative · entry 3 Cline Christopher R. · CIK 0001943192 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,658 F3 · kind: This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. Read SEC document |
| May 06, 2026 Filed May 7, 2026 00:00 UTC |
Dube Eric MDirector · CHIEF EXECUTIVE OFFICER
|
SaleCommon Stock | 22,500 | $43.95 | $988,875.00 |
DisclosureSEC source: 0001763494-26-000006 · form4-05062026_080504.xml · nonDerivative · entry 2 Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 432,886 F2 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. Read SEC document |
| May 05, 2026 Filed May 7, 2026 00:00 UTC |
Inrig JulaCHIEF MEDICAL OFFICER
|
SaleCommon Stock | 2,174 | $46.65 | $101,417.10 |
DisclosureSEC source: 0001902368-26-000006 · form4-05062026_080509.xml · nonDerivative · entry 4 Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 113,549 F3 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| May 05, 2026 Filed May 7, 2026 00:00 UTC |
Baynes Roy D.Director
|
Exercise / conversionStock option (right to buy) · Derivative | 4,500 | $0.00 Strike: $18.27 | $0.00 |
DisclosureSEC source: 0001680739-26-000008 · form4-05062026_080518.xml · derivative · entry 3 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,500 shares Expires 2031-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| May 05, 2026 Filed May 7, 2026 00:00 UTC |
Baynes Roy D.Director
|
SaleCommon Stock | 4,500 | $46.65 | $209,925.00 |
DisclosureSEC source: 0001680739-26-000008 · form4-05062026_080518.xml · nonDerivative · entry 2 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,500 F1 · kind: This sale was made pursuant to a written plan adopted on November 17, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person. Read SEC document |
| May 05, 2026 Filed May 7, 2026 00:00 UTC |
Baynes Roy D.Director
|
Exercise / conversionCommon Stock | 4,500 | $18.27 | $82,215.00 |
DisclosureSEC source: 0001680739-26-000008 · form4-05062026_080518.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2026 Filed May 7, 2026 00:00 UTC |
REED ELIZABETH EChief Legal Officer and GC
|
SaleCommon Stock | 2,174 | $46.65 | $101,417.10 |
DisclosureSEC source: 0001283303-26-000009 · form4-05062026_080511.xml · nonDerivative · entry 4 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 107,287 F3 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| May 05, 2026 Filed May 7, 2026 00:00 UTC |
Heerma PeterCHIEF COMMERCIAL OFFICER
|
SaleCommon Stock | 2,174 | $46.65 | $101,417.10 |
DisclosureSEC source: 0001789617-26-000003 · form4-05062026_080506.xml · nonDerivative · entry 2 Heerma Peter · CIK 0001789617 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,684 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| May 05, 2026 Filed May 7, 2026 00:00 UTC |
Cline Christopher R.CHIEF FINANCIAL OFFICER
|
SaleCommon Stock | 2,181 | $46.65 | $101,743.65 |
DisclosureSEC source: 0001943192-26-000004 · form4-05062026_080501.xml · nonDerivative · entry 2 Cline Christopher R. · CIK 0001943192 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,968 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| May 04, 2026 Filed May 7, 2026 00:00 UTC |
Inrig JulaCHIEF MEDICAL OFFICER
|
Exercise / conversionPerformance-based restricted stock units · Derivative | 4,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001902368-26-000006 · form4-05062026_080509.xml · derivative · entry 8 Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,250 Underlying: Common Stock · 4,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the Issuer's common stock at target, subject to adjustment based on the achievement of applicable performance conditions. F2 · kind: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion. F2 · derivative.exercise_date: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion. F2 · derivative.expiration_date: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion. Read SEC document |
| May 04, 2026 Filed May 7, 2026 00:00 UTC |
Inrig JulaCHIEF MEDICAL OFFICER
|
GrantPerformance-based restricted stock units · Derivative | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001902368-26-000006 · form4-05062026_080509.xml · derivative · entry 7 Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires not disclosed F6 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the Issuer's common stock at target, subject to adjustment based on the achievement of applicable performance conditions. F2 · kind: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion. F2 · derivative.exercise_date: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion. F2 · derivative.expiration_date: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion. Read SEC document |
| May 04, 2026 Filed May 7, 2026 00:00 UTC |
Inrig JulaCHIEF MEDICAL OFFICER
|
Exercise / conversionEmployee stock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $22.40 | $0.00 |
DisclosureSEC source: 0001902368-26-000006 · form4-05062026_080509.xml · derivative · entry 6 Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,500 Underlying: Common Stock · 20,000 shares Expires 2033-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: One-fourth of the shares subject to the stock option vested and become exercisable on January 31, 2024, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| May 04, 2026 Filed May 7, 2026 00:00 UTC |
Inrig JulaCHIEF MEDICAL OFFICER
|
Exercise / conversionCommon Stock | 4,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001902368-26-000006 · form4-05062026_080509.xml · nonDerivative · entry 3 Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 115,723 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion. Read SEC document |
| May 04, 2026 Filed May 7, 2026 00:00 UTC |
Inrig JulaCHIEF MEDICAL OFFICER
|
SaleCommon Stock | 20,000 | $45.00 | $900,000.00 |
DisclosureSEC source: 0001902368-26-000006 · form4-05062026_080509.xml · nonDerivative · entry 2 Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,473 F1 · kind: This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 04, 2026 Filed May 7, 2026 00:00 UTC |
Inrig JulaCHIEF MEDICAL OFFICER
|
Exercise / conversionCommon Stock | 20,000 | $22.40 | $448,000.00 |
DisclosureSEC source: 0001902368-26-000006 · form4-05062026_080509.xml · nonDerivative · entry 1 Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 131,473 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2026 Filed May 7, 2026 00:00 UTC |
Meckler Jeffrey ADirector
|
Exercise / conversionStock option (right to buy) · Derivative | 8,000 | $0.00 Strike: $16.33 | $0.00 |
DisclosureSEC source: 0001506916-26-000001 · form4-05062026_080516.xml · derivative · entry 3 Meckler Jeffrey A · CIK 0001506916 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,000 shares Expires 2026-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| May 04, 2026 Filed May 7, 2026 00:00 UTC |
Meckler Jeffrey ADirector
|
SaleCommon Stock | 8,000 | $45.00 | $360,000.00 |
DisclosureSEC source: 0001506916-26-000001 · form4-05062026_080516.xml · nonDerivative · entry 2 Meckler Jeffrey A · CIK 0001506916 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,500 F1 · kind: This sale was made pursuant to a written plan adopted on November 17, 2025 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person on May 18, 2016 with an expiration date of May 18, 2026. Read SEC document |
| May 04, 2026 Filed May 7, 2026 00:00 UTC |
Meckler Jeffrey ADirector
|
Exercise / conversionCommon Stock | 8,000 | $16.33 | $130,640.00 |
DisclosureSEC source: 0001506916-26-000001 · form4-05062026_080516.xml · nonDerivative · entry 1 Meckler Jeffrey A · CIK 0001506916 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2026 Filed May 7, 2026 00:00 UTC |
ROTE WILLIAM E.Chief Research Officer
|
Exercise / conversionPerformance-based restricted stock units · Derivative | 4,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001698262-26-000004 · form4-05062026_080513.xml · derivative · entry 4 ROTE WILLIAM E. · CIK 0001698262 · Chief Research Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,250 Underlying: Common Stock · 4,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the Issuer's common stock at target, subject to adjustment based on the achievement of applicable performance conditions. F1 · kind: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion. F1 · derivative.exercise_date: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion. F1 · derivative.expiration_date: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion. Read SEC document |
| May 04, 2026 Filed May 7, 2026 00:00 UTC |
ROTE WILLIAM E.Chief Research Officer
|
GrantPerformance-based restricted stock units · Derivative | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001698262-26-000004 · form4-05062026_080513.xml · derivative · entry 3 ROTE WILLIAM E. · CIK 0001698262 · Chief Research Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires not disclosed F3 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the Issuer's common stock at target, subject to adjustment based on the achievement of applicable performance conditions. F1 · kind: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion. F1 · derivative.exercise_date: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion. F1 · derivative.expiration_date: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion. Read SEC document |
| May 04, 2026 Filed May 7, 2026 00:00 UTC |
ROTE WILLIAM E.Chief Research Officer
|
Exercise / conversionCommon Stock | 4,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001698262-26-000004 · form4-05062026_080513.xml · nonDerivative · entry 1 ROTE WILLIAM E. · CIK 0001698262 · Chief Research Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,237 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion. Read SEC document |
| May 04, 2026 Filed May 7, 2026 00:00 UTC |
REED ELIZABETH EChief Legal Officer and GC
|
Exercise / conversionPerformance-based restricted stock units · Derivative | 4,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001283303-26-000009 · form4-05062026_080511.xml · derivative · entry 8 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,250 Underlying: Common Stock · 4,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the Issuer's common stock at target, subject to adjustment based on the achievement of applicable performance conditions. F2 · kind: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion. F2 · derivative.exercise_date: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion. F2 · derivative.expiration_date: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion. Read SEC document |
| May 04, 2026 Filed May 7, 2026 00:00 UTC |
REED ELIZABETH EChief Legal Officer and GC
|
GrantPerformance-based restricted stock units · Derivative | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001283303-26-000009 · form4-05062026_080511.xml · derivative · entry 7 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires not disclosed F6 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the Issuer's common stock at target, subject to adjustment based on the achievement of applicable performance conditions. F2 · kind: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion. F2 · derivative.exercise_date: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion. F2 · derivative.expiration_date: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion. Read SEC document |
| May 04, 2026 Filed May 7, 2026 00:00 UTC |
REED ELIZABETH EChief Legal Officer and GC
|
Exercise / conversionEmployee stock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $17.96 | $0.00 |
DisclosureSEC source: 0001283303-26-000009 · form4-05062026_080511.xml · derivative · entry 6 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2029-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| May 04, 2026 Filed May 7, 2026 00:00 UTC |
REED ELIZABETH EChief Legal Officer and GC
|
Exercise / conversionCommon Stock | 4,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001283303-26-000009 · form4-05062026_080511.xml · nonDerivative · entry 3 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,461 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.